Ethical approval and consent to participate

COTA database houses de-identified and secondary data; it is not anticipated that studies using these particular sources present any risk to human subjects. Ethics approval for the NHL-1 trial has been previously published, and this study utilized individual patient-level data from that clinical trial.

Consent for publication

Not applicable.

Competing interests

Allison Rosenthal: Educational Workshop Speaker Role: RMEI, Curio Science, Targeted Oncology, OncLiveU. Javier Munoz: Consulting: Pharmacyclics/AbbVie, Bayer, Gilead/Kite, Pfizer, Janssen, Juno/Celgene, BMS, Kyowa, Alexion, Fosunkite, Innovent, Seattle Genetics, Debiopharm, Karyopharm, Genmab, ADC Therapeutics, Epizyme, BeiGene, Servier, Novartis, MorphoSys/Incyte, Secura Bio, TG Therapeutics, MEI, Lilly/Loxo; Research Funding: Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium; Honoraria: Targeted Oncology, OncView, Curio, Kyowa, Physicians’ Education Resource, Seattle Genetics; Speakers Bureau: Gilead/Kite, Kyowa, Bayer, Pharmacyclics/Janssen, Seattle Genetics, Acrotech/Aurobindo, BeiGene, Verastem, AstraZeneca, Celgene/BMS, Genentech/Roche. Monika Jun, Tongsheng Wang, Alex Mutebi, Fernando Rivas Navarro, Samantha Brodkin, Mariana Sacchi: Genmab: Current Employment. Brian Elliott: Genmab: Current Employment and Stockholder. Shibing Yang: Genmab: Former Employment. Anthony Wang, Kojo Osei-Bonsu, Junhua Yu: AbbVie: Current Employment. Andrew Ip: Honoraria: Pfizer; Speakers Bureau: Seagen; Advisory Board: Secura Bio, AstraZeneca, TG Therapeutics.